Background Angiotensin-converting enzyme (ACE) inhibitors prevent the expansion and
rupture of aortic aneurysms in animals. We investigated the association between ACE …

OBJECTIVES: To evaluate whether either angiotensin converting enzyme (ACE) inhibitors
or other classes of antihypertensive drug attenuate or increase growth rates of small …

Objective: The aim of this study was to investigate the association between anti-hypertensive
drugs, the risk of developing an abdominal aortic aneurysm (AAA), aortic wall stiffness …

OBJECTIVE: To review current literature relating to the adverse effects of the angiotensin-
converting enzyme (ACE) inhibitors. DATA SOURCES: Online drug information sources …

Rationale, aims and objectives To identify potential factors leading to discontinuation of
angiotensin‐converting enzyme (ACE) inhibitors because of adverse drug events. Methods …

Angiotensin-converting enzyme (ACE) inhibitors are well established as first-line therapy for
patients with left ventricular dysfunction, diabetic patients with hypertension or renal disease …

Purpose: Pathologic remodeling of the extracellular matrix is a critical mechanism in the
development and progression of abdominal aortic aneurysms (AAAs). Although angiotensin …

BACKGROUND: Animal models have demonstrated a benefit of angiotensin-converting
enzyme inhibitors (ACEI) in experimental aortic stenosis (AS), and intravenous nitroprusside …

Aims The AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition
on RisK) trial investigated whether ACE-inhibition reduces small abdominal aortic …

When first introduced in 1981, angiotensin-converting enzyme (ACE) inhibitors were
indicated only for treatment of refractory hypertension. Since then, they have been shown to …